Yamazaki, Yukiyoshi; Abe, Kazutoyo; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Araki, Takaaki; Oda, Soichi; Inoue, Keisuke; Shibuya, Kimiyuki; Staels, Bart; Fruchart, Jean-Charles published the artcile< Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists>, Reference of 13451-78-0, the main research area is aryloxyalkyl benzoxazole substituted aminoalkyl aryloxyalkanoic acid preparation PPAR agonist; structure aminoalkyl aryloxyalkanoic acid activity selectivity PPAR alpha agonist; hypolipemic activity PPAR binding selectivity aminoalkyl aryloxyalkanoic acid.
Aryloxyalkanoic acids substituted with aryloxyalkyl and benzoxazole-substituted aminoalkyl groups such as I are prepared as human peroxisome proliferator-activated receptor α (PPAR-α) agonists for decreasing lipid levels; the binding of the compounds to PPAR-α, PPAR-δ, and PPA-γ and the decreases in liver weight and triglyceride levels in rats upon administration of the sodium salts of three of the compounds are determined The racemate of I is prepared and resolved by HPLC to provide I and its enantiomer; I inhibits PPAR-α with an EC50 value of 1 nM and approx. 1000-fold selectivity over PPAR-δ and PPAR-γ, while the sodium salt of I decreases triglyceride concentrations in rats by approx. 49%.
Bioorganic & Medicinal Chemistry Letters published new progress about Apolipoprotein A-I Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 13451-78-0 belongs to class benzoxazole, and the molecular formula is C7H4FNOS, Reference of 13451-78-0.
Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem